Search Results - "Chu, Seung Y"

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody by Chu, Seung Y., PhD, Horton, Holly M., PhD, Pong, Erik, MS, Leung, Irene W.L., PhD, Chen, Hsing, MS, Nguyen, Duc-Hanh, BS, Bautista, Cristina, BS, Muchhal, Umesh S., PhD, Bernett, Matthew J., PhD, Moore, Gregory L., PhD, Szymkowski, David E., PhD, Desjarlais, John R., PhD

“…Background Sequestration of IgE to prevent its binding to high-affinity IgE receptor FcϵRI on basophils and mast cells is an effective therapy for allergic…”
Get full text

A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens by Moore, Gregory L., Bautista, Cristina, Pong, Erik, Nguyen, Duc-Hanh T., Jacinto, Jonathan, Eivazi, Araz, Muchhal, Umesh S., Karki, Sher, Chu, Seung Y., Lazar, Greg A.

“…Bispecific antibodies based on full-length antibody structures are more optimal than fragment-based formats because they benefit from the favorable properties…”
Get full text

Fc-engineered anti-CD40 antibody enhances multiple effector functions and exhibits potent in vitro and in vivo antitumor activity against hematologic malignancies by Horton, Holly M., Bernett, Matthew J., Peipp, Matthias, Pong, Erik, Karki, Sher, Chu, Seung Y., Richards, John O., Chen, Hsing, Repp, Roland, Desjarlais, John R., Zhukovsky, Eugene A.

“…CD40 is highly expressed on various B-lineage malignancies and represents an attractive immunotherapy target for neoplastic disease. Previous work showed that…”
Get full text

Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice by Chu, Seung Y., Pong, Erik, Bonzon, Christine, Yu, Ning, Jacob, Chaim O., Chalmers, Samantha A., Putterman, Chaim, Szymkowski, David E., Stohl, William

“…Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. Obexelimab is a…”
Get full text

Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function by Tai, Yu-Tzu, Horton, Holly M., Kong, Sun-Young, Pong, Erik, Chen, Hsing, Cemerski, Saso, Bernett, Matthew J., Nguyen, Duc-Hanh T., Karki, Sher, Chu, Seung Y., Lazar, Greg A., Munshi, Nikhil C., Desjarlais, John R., Anderson, Kenneth C., Muchhal, Umesh S.

“…HM1.24, an immunologic target for multiple myeloma (MM) cells, has not been effectively targeted with therapeutic monoclonal antibodies (mAbs). In this study,…”
Get full text

A robust heterodimeric Fc platform engineered for efficient development of bispecific antibodies of multiple formats by Moore, Gregory L., Bernett, Matthew J., Rashid, Rumana, Pong, Erik W., Nguyen, Duc-Hanh T., Jacinto, Jonathan, Eivazi, Araz, Nisthal, Alex, Diaz, Juan E., Chu, Seung Y., Muchhal, Umesh S., Desjarlais, John R.

“…•A novel heterodimeric Fc platform for creating bispecific antibodies is presented.•Heterodimer yields over 95% are achieved with little change in Fc…”
Get full text

Transmembrane tumour necrosis factor is neuroprotective and regulates experimental autoimmune encephalomyelitis via neuronal nuclear factor-κB by Taoufik, Era, Tseveleki, Vivian, Chu, Seung Y., Tselios, Theodore, Karin, Michael, Lassmann, Hans, Szymkowski, David E., Probert, Lesley

“…Tumour necrosis factor mediates chronic inflammatory pathologies including those affecting the central nervous system, but non-selective tumour necrosis factor…”
Get full text

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia by HORTON, Holly M, BERNETT, Matthew J, DESJARLAIS, John R, ZHUKOVSKY, Eugene A, PONG, Erik, PEIPP, Matthias, KARKI, Sher, CHU, Seung Y, RICHARDS, John O, VOSTIAR, Igor, JOYCE, Patrick F, REPP, Roland

“…CD19 is a pan B-cell surface receptor expressed from pro-B-cell development until its down-regulation during terminal differentiation into plasma cells. CD19…”
Get full text

Crystal Structure of the YchF Protein Reveals Binding Sites for GTP and Nucleic Acid by Teplyakov, Alexey, Obmolova, Galina, Chu, Seung Y, Toedt, John, Eisenstein, Edward, Howard, Andrew J, Gilliland, Gary L

“…Article Usage Stats Services JB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in systemic lupus erythematosus by Horton, Holly M, Chu, Seung Y, Ortiz, Elizabeth C, Pong, Erik, Cemerski, Saso, Leung, Irene W L, Jacob, Noam, Zalevsky, Jonathan, Desjarlais, John R, Stohl, William, Szymkowski, David E

“…Engagement of the low-affinity Ab receptor FcγRIIb downregulates B cell activation, and its dysfunction is associated with autoimmunity in mice and humans. We…”
Get full text

Accelerated Clearance and Degradation of Cell-Free HIV by Neutralizing Antibodies Occurs via FcγRIIb on Liver Sinusoidal Endothelial Cells by Endocytosis by Turman, James M, Cheplowitz, Alana M, Tiwari, Charu, Thomas, Thushara, Joshi, Dhruvi, Bhat, Menakshi, Wu, Qian, Pong, Erik, Chu, Seung Y, Szymkowski, David E, Sharma, Amit, Seveau, Stephanie, Robinson, John M, Kwiek, Jesse J, Burton, Dennis, Rajaram, Murugesan V S, Kim, Jonghan, Hangartner, Lars, Ganesan, Latha P

“…Neutralizing Abs suppress HIV infection by accelerating viral clearance from blood circulation in addition to neutralization. The elimination mechanism is…”
Get full text

Suppression of Rheumatoid Arthritis B Cells by XmAb5871, an Anti‐CD19 Antibody That Coengages B Cell Antigen Receptor Complex and Fcγ Receptor IIb Inhibitory Receptor by Chu, Seung Y., Yeter, Karen, Kotha, Roshan, Pong, Erik, Miranda, Yvonne, Phung, Sheryl, Chen, Hsing, Lee, Sung‐Hyung, Leung, Irene, Bonzon, Christine, Desjarlais, John R., Stohl, William, Szymkowski, David E.

“…Objective Engagement of Fcγ receptor IIb (FcγRIIb) suppresses B cell activation and represents a promising target for therapy in autoimmunity. The aim of this…”
Get full text

Abstract 5549: Potency-reduced IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity by Varma, Rajat, Liu, Ke, Bonzon, Christine, Rashid, Rumana, Rodriguez, Nicole, Hassanzadeh-Kiabi, Nargess, Ardila, Connie, Chu, Seung Y., Muchhal, Umesh S., Desjarlais, John R., Bernett, Matthew J.

“…Interleukin-12 (IL12) is a proinflammatory cytokine produced by activated antigen-presenting cells that induces differentiation of Th1 cells and increased…”
Get full text

Optimizing engagement of the immune system by anti-tumor antibodies: an engineer's perspective by Desjarlais, John R., Lazar, Greg A., Zhukovsky, Eugene A., Chu, Seung Y.

“…A unique property of monoclonal antibodies, and a principal reason for their success as cancer therapeutics, is their ability to engage the immune system. A…”
Get full text

The impact of Fc engineering on an anti-CD19 antibody: increased Fcγ receptor affinity enhances B-cell clearing in nonhuman primates by Zalevsky, Jonathan, Leung, Irene W.L., Karki, Sher, Chu, Seung Y., Zhukovsky, Eugene A., Desjarlais, John R., Carmichael, David F., Lawrence, Chris E.

“…CD19, a B cell–restricted receptor critical for B-cell development, is expressed in most B-cell malignancies. The Fc-engineered anti-CD19 antibody, XmAb5574,…”
Get full text

Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies by Chu, Seung Y., Vostiar, Igor, Karki, Sher, Moore, Gregory L., Lazar, Greg A., Pong, Erik, Joyce, Patrick F., Szymkowski, David E., Desjarlais, John R.

“…The humoral immune response requires antigen-specific B cell activation and subsequent terminal differentiation into plasma cells. Engagement of B cell antigen…”
Get full text

1060 Optimally engineered IL18 Fc-fusion proteins balance potency and pharmacokinetics to promote strong anti-tumor activity by Nisthal, Alex, Lee, Sung-Hyung, Bonzon, Christine, Love, Ruschelle, Avery, Kendra N, Rashid, Rumana, Lertkiatmongkol, Panida, Rodriguez, Nicole, Leung, Irene, Karki, Sher, Barlow, Norman J, Chu, Seung Y, Moore, Gregory L, Desjarlais, John R

“…BackgroundInterleukin-18 (IL18) promotes expansion, survival, and cytotoxicity of T and NK cells. Tumor-experienced T cells upregulate the heterodimeric IL18…”
Get full text

Abstract 5000: Immunotherapy with anti-PSMA x anti-CD3 bispecific antibody stimulates potent killing of a human prostate cancer cell line and target-mediated T cell activation in monkeys: A potential therapy for prostate cancer by Chu, Seung Y., Pong, Erik W. K., Rashid, Rumana, Chen, Hsing, Chan, Emily W., Phung, Sheryl, Endo, Nancy A., Ardila, Maria C., Bonzon, Christine, Leung, Irene W. L., Muchhal, Umesh S., Moore, Gregory L., Bernett, Matthew J., Desjarlais, John R., Szymkowski, David E.

“…PSMA (Prostate-Specific Membrane Antigen) is a promising therapeutic target in prostate cancer. Exploiting the high and selective expression of PSMA in the…”
Get full text

Suppression of mast cell degranulation through a dual-targeting tandem IgE–IgG Fc domain biologic engineered to bind with high affinity to FcγRIIb by Cemerski, Saso, Chu, Seung Y, Moore, Gregory L, Muchhal, Umesh S, Desjarlais, John R, Szymkowski, David E

“…Highlights ► We generated an Fcε–Fcγ fusion protein (tandem Fc) to suppress mast cell activation. ► Enhanced binding to FcγRIIb via Fc engineering…”
Get full text

Immune suppression in cynomolgus monkeys by XPro9523: An improved CTLA4-Ig fusion with enhanced binding to CD80, CD86 and neonatal Fc receptor FcRn by Bernett, Matthew J., Chu, Seung Y., Leung, Irene, Moore, Gregory L., Lee, Sung-Hyung, Pong, Erik, Chen, Hsing, Phung, Sheryl, Muchhal, Umesh S., Horton, Holly M., Lazar, Greg A., Desjarlais, John R, Szymkowski, David E.

“…The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant,…”
Get full text